Clinical Trials Logo

Cognitive Deterioration clinical trials

View clinical trials related to Cognitive Deterioration.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06056934 Recruiting - Clinical trials for Cognitive Deterioration

Pain Management in Elderly Patients With or Without Cognitive Frailty Hospitalized "ALGOGER"

ALGOGER
Start date: March 9, 2023
Phase:
Study type: Observational

Today, the standard treatment is to operate on patients suffering from a fracture of the upper end of the femur. The aim of treatment is to enable immediate mobilization and weight-bearing, and as rapid a return as possible to normal living conditions. Surgery is the best treatment option. It maximizes the chances of functional recovery and, by stabilizing the fracture, reduces pain: it is the most effective and longest-lasting analgesic. Adequate analgesia in elderly patients with femoral neck fractures has a beneficial effect. In particular, a lower probability of death has been shown in cervical fracture patients receiving opioids than those not receiving them. Pain management is a matter of protocol in the UPOG department of the CHU de Nîmes. Pain prevention appears to improve morbidity and mortality. Cognitive fragility, such as neurocognitive disorders, confusion or long-term use of psychotropic drugs, appear to be confounding factors in pain management. The investigators therefore wished to observe whether the presence of cognitive fragility has an impact on pain management on the ward, despite protocol-based management.

NCT ID: NCT05728801 Recruiting - Clinical trials for Age-related Cognitive Decline

Decoding the Cognitive Trajectory of Hong Kong SuperAgers: a Longitudinal Follow-up Study

Start date: June 1, 2022
Phase:
Study type: Observational

This is a prospective follow-up study conducted at the Department of Psychiatry, The Chinese University of Hong Kong. The participants, including high-performing elderly (SuperAgers), normal ageing elderly and neurocognitive disorder (NCD) patients will be re-invited from our previous cohort (2013-2014) (N=488).

NCT ID: NCT05497427 Recruiting - Cognitive Decline Clinical Trials

Normative Database and Test-Retest Reliability for BrainCheck Assessments

NDTR
Start date: October 10, 2022
Phase:
Study type: Observational

The purpose of this study is to collect normative test values and demographic information for normative and referential data for a rapid, portable, computerized neurocognitive testing device from healthy adults 50 and older.

NCT ID: NCT04263194 Recruiting - Alzheimer Disease Clinical Trials

Network-based rTMS in Alzheimer's Disease

Start date: March 21, 2019
Phase: N/A
Study type: Interventional

Severe alterations of brain networks connectivity have been described in Alzheimer's disease (AD). Repetitive Transcranial Magnetic Stimulation (rTMS) has gained evidence as an effective tool to modulate brain networks connectivity, leading to a recovery or reorganization of both local and remote brain regions functionally connected to the stimulated area. The investogators propose an innovative tailored network-based rTMS treatment to ameliorate cognitive symptoms in mild AD, through the boosting of connectivity within brain networks affected by AD pathophysiology. The combination of the proposed intervention with an integrated multi-modal imaging approach will allow to evaluate the neural mechanisms underlying the clinical response to the treatment and to define quantitative markers of clinical impact on AD. If successful, the present proposal would immediately impact on patient's quality of life, with important implications for the time and costs of delivery of rehabilitative services.

NCT ID: NCT03657745 Recruiting - Alzheimer Disease Clinical Trials

Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy

AlzLife
Start date: January 1, 2018
Phase:
Study type: Observational

Electrical activity in the brain known as "gamma" brainwaves help connect and process information throughout the brain. These gamma waves are diminished in Alzheimer's disease. New research in Alzheimer's disease mouse models shows that exposure to light flickering at the rate of 40 flashes per second or 40Hz increased gamma brainwaves and led to clearing of beta amyloid plaques in the brain, a key abnormality in Alzheimer's disease. This project will test the ability of a novel iPad App (AlzLife https://www.alz.life/) that delivers light therapy at 40 Hz combined with cognitive therapy to improve cognition, function, and quality of life in Alzheimer's disease.